a Open Access Full Text Article

# ORIGINAL RESEARCH **Causal Paradigm Between Common Comorbidities** of Cardiovascular and Metabolism-Related Diseases in Elderly: Evidence from Cross-Sectional and Mendelian Randomization Studies

Junwang Gu\*, Qi Wang\*, Xuanhui Wu, Han Zhang, Chunmei Wu, Wei Qiu

School of Public Health and Health Management, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Wei Qiu; Chunmei Wu, Tel/Fax +86-7978169236, Email gw21046@163.com; wuchunmei82@gg.com

Background: Comorbidity is a common problem among elderly people, significantly damaging individuals' health and healthcare systems. However, observational studies may be susceptible to residual confounding factors and bias. The present study aimed to assess the causal effect of common chronic disease comorbidity using the Mendelian randomization (MR) approach.

Methods: Data for the present study were obtained from a community survey conducted between 2018 and 2020 in four counties in Ganzhou City, southern China. A cross-sectional survey was conducted using a multi-stage stratified random sampling method. A total of 1756 valid questionnaires were collected to analyze common chronic disease comorbidities. Genetic variants associated with hypertension, diabetes, stroke, and hyperlipidemia-related factors were selected as instrumental variables for univariate and multivariate MR analyses.

**Results:** The self-reported prevalence of chronic disease in the older adult population in Southern China was 68.1%, with hypertension (46.1%), diabetes (10.5%), and hyperlipidemia (8.5%) being the three most common conditions. The prevalence of chronic disease comorbidity was 20.7% among the 12 chronic diseases studied. Hypertension was identified as a predictor of diabetes (OR [95% CI]: 1.114 [1.049, 1.184], p < 0.001), and diabetes mellitus was equally identified as a risk factor for hypertension (OR [95% CI]: 1.118 [1.069, 1.187], p < 0.001). Furthermore, high triglyceride levels were identified as a risk factor for hypertension (OR [95% CI]: 1.262 [1.129, 1.411],  $p \le 0.001$ ). In contrast to intracranial hemorrhages, hypertension had a significant impact on ischemic stroke (*OR* [95% *CI*]: 1.299 [1.161, 1.454], *p* < 0.001).

**Conclusion:** The causal association between multiple cardiovascular and metabolism-related diseases is mediated by hypertension, with a bidirectional cause-and-effect relationship between hypertension and diabetes. Hypertension is a risk factor for ischemic stroke, and the hyperlipidemia-related factor triglycerides (TG) influence hypertension. Therefore, prioritizing hypertension prevention and control in the elderly is critical for effective chronic disease management.

Keywords: hypertension, diabetes, hyperlipidemia, stroke, causal, mendelian randomization

### Introduction

Chronic diseases, also known as non-communicable chronic diseases (NCDs), are a group of diseases caused by a combination of genetic, physiological, environmental, and behavioral factors. They have an insidious onset, a long course, and no clear etiology. Chronic diseases are major killers in the modern era, accounting for most healthcare expenditures. They are also increasingly becoming a health burden in lower- and middle-income countries, putting pressure on public health efforts to scale up interventions.<sup>1,2</sup>

Multimorbidity or comorbidities, the coexistence of two or more chronic diseases, is a common problem in the elderly and is significantly associated with increased mortality, disability, and functional decline.<sup>3,4</sup> Information on chronic disease interactions can help diagnose and prevent.<sup>5</sup> The link between these diseases is complex and is mediated by common risk factors, notably smoking and physical inactivity.<sup>6</sup> A cross-sectional study revealed that having one cardiovascular disease (CVD) increased the risk of co-occurring CVD and many other chronic diseases. However, the etiology of chronic disease comorbidities remains unknown. Given the high incidence and prevalence of chronic disease comorbidity, the assumption that chronic diseases are mutually causal appears acceptable However, because of the difficulty in designing such longitudinal studies, such causal relationships have rarely been investigated. Despite the rigorous design and analysis of traditional observational epidemiological studies, it remains challenging to exclude confounding factors, and there are shortcomings in clarifying causality when arguing for causality in complex diseases such as chronic diseases.<sup>7</sup> Randomized controlled trials (RCTs) are the most effective method for proving the etiological hypothesis in epidemiological studies because they can minimize potential biases in clinical trial design and implementation, balance confounding factors, and time required.<sup>8</sup> Therefore, this study used Mendelian randomization (MR) to overcome the limitations of traditional studies.

MR is a statistical approach that uses single-nucleotide polymorphisms (SNPs) as instrumental variables (IVs) to determine the relationship between risk factors and disease outcomes. MR can significantly reduce the risk of confounding and reverse causation, which are shortcomings of conventional epidemiological studies.<sup>9</sup> The present study aims to investigate the causal relationship between common chronic disease comorbidities. To achieve this objective, we obtained data from a community survey of chronic diseases among older adults in southern China to identify common disease comorbidities. Subsequently, we used public summary data from a genome-wide association study (GWAS) to conduct an MR study to investigate causal associations among chronic diseases. The findings of the present study may contribute to improving the understanding of the development and causal relationships of chronic disease comorbidity, thereby increasing the value of chronic disease prevention and management.

### **Materials and Methods**

#### **Participants**

A multistage stratified random sampling method was used to conduct cross-sectional community surveys between 2018 and 2020 in Ganzhou City, southern China, to collect self-reported data on chronic diseases of the elderly through questionnaires.

The investigation area for this study comprised four county-level districts, namely Zhanggong, Ganxian, Nankang, and Xinfeng districts in Ganzhou City, as illustrated in Figure S1. The study targeted permanent residents aged 18 years and above who had resided in the area for at least six months. The survey was conducted in collaboration with the township health center under the guidance of the related county Health Commission and was organized by the Centers for Disease Control and Prevention (CDC). The program design, on-site investigation, and residents' health examinations were all conducted under the auspices of these entities. After eliminating questionnaires with significant errors, such as duplicate and unreliable questionnaires, 1756 valid questionnaires were collected from older respondents.

### Definitions

The present study includes twelve types of chronic diseases, and respondents were defined as chronic disease comorbidities if they had been diagnosed with two or more.

The risk ratios (RR) and observed-to-expected ratios (O/E) of comorbidity indicators between diseases were used to calculate the correlation.<sup>10</sup> The RR value for a chronic disease indicates the likelihood of a comorbid person suffering from a specific chronic disease compared with non-comorbid persons. This is equal to the prevalence of comorbid patients divided by the prevalence of non-comorbid patients. A higher RR value indicates that there are more comorbidities than non-comorbidities and that the disease is more likely to coexist with other diseases. However, there is no direct relationship between comorbidity risk and prevalence.

The O/E ratio was calculated to estimate conditional probabilities of combinations of two chronic conditions and is equal to the ratio of observed and expected prevalence of co-modality. The predicted prevalence of co-modality is the product of the respective prevalence of chronic diseases included in the co-modality.

# MR Study

### GWAS Summary Data

All GWAS summary statistics used in the current MR study were obtained from the IEU Open GWAS Project summary datasets (<u>https://gwas.mrcieu.ac.uk/</u>). Because we only analyzed publicly available summary-level GWAS data, the MR study was exempt from ethical review. Table 1 presents the detailed information.

### IVs Selection

The extracted genetic variants were selected as IVs to estimate causal effects in chronic diseases based on the following assumptions: (1) predictive of exposure variables, (2) independent of confounders, and (3) no change in outcome variables via an independent pathway other than exposure. We first used the SNPs associated with exposure variables at genome-wide significance ( $p < 5 \times 10^{-8}$ ), then pruned for linkage disequilibrium (LD) ( $r^2 < 0.001$ , distance < 10,000 kb) to obtain independent SNPs. The F statistic ( $F = beta^2/se^2$ ) was used to evaluate the potency of the instrumental variable (IV) to avoid potentially weak instrumental bias. A value of F greater than ten indicates a strong correlation between IV and exposure, protecting the MR analysis results from the effects of weak instrumental bias. <sup>11,12</sup> Each exposure-associated SNP was then examined for potential Assumptions 2 and 3 violations using GWAS database. SNPs associated with known risk factors for the outcome variables were excluded from further investigation. A PhenoScanner V2 search was performed to identify confounding phenotypes related to the selected IVs.<sup>13,14</sup> The remaining SNPs were aggregated with GWAS outcome variable database, removing those not included in the outcome variable database. Palindromic SNPs with intermediate allele

Datasets	GWAS ID	Population	Author	Year	Consortium	Sample Size	Sex	Traits
Hypertension	finn-b-19_HYPTENS	European	NA	2021	NA	55917 cases and 162837 controls	Male and Female	Hypertension
Diabetes	finn-b-E4_DIABETES	European	NA	2021	NA	35607 cases and 18318 controls	Male and Female	Diabetes mellitus
Hyperlipidemia	met-d-Total_C	European	Borges CM	2020	NA	115078	Male and Female	Total cholesterol
	ieu-b-111	European	Richardson, Tom	2020	UK Biobank	441016	Male and Female	Triglycerides
	ieu-b-110	European	Richardson, Tom	2020	UK Biobank	440546	Male and Female	LDL cholesterol
	ieu-b-109	European	Richardson, Tom	2020	UK Biobank	403943	Male and Female	HDL cholesterol
Stroke	finn-b-C_STROKE	European	NA	2021	NA	18661 cases and 162201 controls	Male and Female	Stroke
	finn-b-19_STR_EXH	European	NA	2021	NA	10551 cases and 202223 controls	Male and Female	lschemic Stroke, excluding all hemorrhages
	finn- b-19_OTHINTRACRA	European	NA	2021	NA	331 cases and 203068 controls	Male and Female	Other intracranial hemorrhages

Table I Detailed Information on GWAS Datasets Used in This MR Study

Abbreviation: NA, is not applicable.

frequencies (MAF threshold = 0.3) were removed. The MRORESSO test also removes SNPs with potentially pleiotropic outliers.<sup>15</sup> Figure 1 depicts the SNPs selection process for the univariate MR study.


### Statistical Analysis

As the primary MR method in this two-sample MR analysis, we used the inverse variance weighted (IVW) method implemented in the TwoSampleMR R package. If the selected SNPs meet IV assumptions, this method provides the most reliable causal assessment and has the highest statistical power.<sup>16</sup> We then performed sensitivity analyses using MR-Egger, weighted median, weighted mode, simple mode, and maximum likelihood methods to evaluate the robustness of the findings. The intercept of the MR-Egger regression method was used to measure the effect size of horizontal pleiotropy. The closer the intercept to zero, the smaller the horizontal pleiotropy, and p > 0.05 of the horizontal pleiotropy test was considered to indicate no horizontal pleiotropy.<sup>17</sup> We also ran a leave-one-out sensitivity analysis to evaluate whether individual IVs drove the observed causal associations. Cochran's *Q* statistical test was used to assess the presence of heterogeneity between the variant-specific estimates. All statistical analyses, including univariate and multivariate MR, were performed in *R* (version 4.2.3) using the package "TwoSampleMR" (version 0.5.6).<sup>18,19</sup> Statistical significance was set at p < 0.05.

# Results

# Characteristics of Respondents

The demographic characteristics of the respondents are summarized in Table 2. Among the total sample, 830 (47.3%) were male, and 926 (52.7%) were female. Most of the respondents (98.7%) were Han Chinese. The sample had a mean age of  $68.92 \pm 7.41$  years, with men having a mean age of  $68.72 \pm 6.87$  years and women having a mean age of  $69.10 \pm 7.86$  years. Only two (0.1%) respondents had an undergraduate or higher level of education. Most respondents (60.2%) were unemployed, jobless or retired. Approximately 38.5% of the respondents reported a monthly average income per capita of  $\geq 1000$  and < 3000 Yuan, while 23.6% reported an income of  $\geq 3000$  and < 5000 Yuan.



#### Figure I IVs selection flow.

Abbreviations: MR, Mendelian Randomization; LD, Linkage disequilibrium, SNPs, Single nucleotide polymorphisms.

Variables	Grouping	Frequency (Valid Percent [%])	
Sex	Men	830 (47.3)	
	Women	926 (52.7)	
Ethnic	Hans	1733 (98.7)	
	Others	23 (1.3)	
Education	No formal school education	332 (18.9)	
	Did not finish primary school	402 (22.9)	
	Primary school	432 (24.6)	
	Junior high school	301 (17.1)	
	Senior high school and technical secondary school	239 (13.6)	
	Junior college	31 (1.8)	
	Undergraduate and above	2 (0.1)	
	Missing values	17(1.0)	
Occupation	Institutional and enterprise staff	25 (1.4)	
	Scientific and technical staff	6 (0.3)	
	Other workers	660 (37.6)	
	Not working, such as jobless and retired	1057 (60.2)	
	Missing values	8 (0.4)	
The monthly average income per capita (Yuan)	< 500	118 (6.7)	
	≥ 500 and < 1000	199 (11.3)	
	≥ 1000 and < 3000	676 (38.5)	
	≥ 3000 and < 5000	414 (23.6)	
	≥ 5000	163 (9.3)	
	Missing values	186 (10.6)	

#### Table 2 Characteristics of Respondents

# Self-Reported Prevalence of Chronic Diseases Among the Elderly in Southern China

Of the 1756 participants, 1195 residents had at least one chronic disease, resulting in a self-reported prevalence of 68.1%. The prevalence rates of the 12 common chronic diseases in this survey were arranged in descending order (Figure 2), with hypertension having the highest prevalence rate (46.1%), followed by diabetes (10.5%), hyperlipidemia (8.5%), coronary artery disease (6.1%), chronic bronchitis (5.4%), osteoporosis (4.4%), stroke (2.8%), prostatic hypertrophy (1.9%), cataract (1.5%), malignant tumor (0.6%), mental illness (0.3%), and chronic hepatitis (0.3%).

### Chronic Disease Comorbidity in the Elderly

The present study examined the prevalence and pattern of chronic comorbidities in the elderly. The correlation among the components of chronic disease comorbidity was estimated by calculating the relative RR and O/E ratio of the comorbidity.

The survey included 12 chronic diseases, and the results indicated a prevalence of chronic disease comorbidity of 20.7% (364/1756), with 28 different types of dyad comorbidity (Figure 3). Among the 12 chronic diseases examined, the following conditions exhibited a heightened risk of comorbidity: hyperlipidemia (RR = 6.14), prostatic hypertrophy (RR = 5.60), stroke (RR = 3.90), coronary artery disease (RR = 3.28), diabetes (RR = 2.78), chronic bronchitis (RR = 1.79), osteoporosis (RR = 1.60), cataract (RR = 1.0), hypertension (RR = 0.68), chronic hepatitis (RR = 0.67), malignant tumor (RR = 0.57), and mental illness (RR = 0.25). Correlation analysis revealed that the dyad comorbidity with the highest O/E (4.837) was a malignant tumor and prostatic hypertrophy. Figure 3 depicts the prevalence and correlations of dyad chronic diseases of comorbidities.

Based on the prevalence and association probability (indicated by O/E values) of comorbidity patterns, the dyad comorbidity patterns of chronic disease with both prevalence and O/E values ranking in the top eight were selected in the subsequent MR study. Finally, three dyad disease comorbidity patterns, namely, hypertension and diabetes, hypertension and hyperlipidemia, and hypertension and stroke, were included in the next step.




Figure 2 Self-reported prevalence of the chronic diseases.

### Causal Relationships Between Chronic Diseases

#### Hypertension and Diabetes

Hypertension and diabetes are common chronic diseases that affect a large proportion of the adult population. Hypertension and diabetes mellitus are "silent killers" with an increasing global prevalence. Hypertension is a common diabetes comorbidity and a mortality risk factor.<sup>20</sup> High blood pressure (BP) is reported in more than two-thirds of patients with type 2 diabetes (T2D), and its onset coincides with hyperglycemia.<sup>21</sup> High BP is associated with a higher risk of diabetes.<sup>22</sup> Hypertension accelerates the progression of diabetic nephropathy through glomerular hyperfiltration and causes atherosclerosis in diabetes.<sup>23</sup> In the current observational studies, diabetes mellitus was associated with an increased risk of hypertension and vice versa, but the causality between these conditions is yet to be determined.

A 4-year follow-up study revealed that high BP is a risk factor for T2D in middle-aged and elderly Chinese.<sup>24</sup> The highest diastolic BP and longest hypertension duration were independently associated with T2D in hypertensive subjects.<sup>25</sup> A prospective cohort study indicated that diabetes was associated with hypertension and arterial stiffness, with arterial stiffness predicting diabetes better than hypertension.<sup>26</sup>

In contrast, observational evidence revealed that diabetic or obese patients frequently have morning hypertension.<sup>27</sup> A case-control study demonstrated that diabetes was a significant risk factor for hypertension and that diabetes positively interacted with hypertension.<sup>28</sup> Therefore, we hypothesized that hypertension and diabetes are causally linked. The literature was searched, and a few MR studies were found to elaborate on their causal association.<sup>29,30</sup> However, the results were inconsistent, probably because of the different samples and the use of differentiated IVs. Therefore, by

Comorbid	ity pattern	Prevalence (%)	O/E value	
				0.040
Hypertension	Diabetes	3.645	0.751	0.040
Hypertension	Hyperlipidemia	3.189	0.810	
Hypertension	Chronic bronchitis	1.708	0.685	
Hypertension	Stroke	1.310	1.019	
Hypertension	Coronary artery disease	1.253	0.446	rtoranti, televisiv
Hypertension	Osteoporosis	0.854	0.417	- 1.000
Hypertension	Prostatic hypertrophy	0.513	0.592	
Hyperlipidemia	Diabetes	0.342	0.380	
Hypertension	Cataract	0.228	0.334	
Coronary artery disease	Chronic bronchitis	0.171	0.518	
Diabetes	Osteoporosis	0.171	0.365	1.900
Coronary artery disease	Hyperlipidemia	0.171	0.328	- 1.960
Cataract	Prostatic hypertrophy	0.114	4.093	
Hypertension	Chronic hepatitis	0.114	0.868	
Osteoporosis	Chronic bronchitis	0.114	0.474	
Stroke	Diabetes	0.114	0.387	
Malignant tumor	Prostatic hypertrophy	0.057	4.837	- 2.920
Diabetes	Mental illness	0.057	1.898	
Coronary artery disease	Malignant tumor	0.057	1.492	
Chronic bronchitis	Cataract	0.057	0.711	
Coronary artery disease	Cataract	0.057	0.631	
Stroke	Osteoporosis	0.057	0.459	5.000
Stroke	Chronic bronchitis	0.057	0.377	- 3.880
Diabetes	Cataract	0.057	0.365	
Coronary artery disease	Osteoporosis	0.057	0.210	
Hyperlipidemia	Osteoporosis	0.057	0.150	
Hyperlipidemia	Chronic bronchitis Chronic bronchitis	0.057 0.057	0.100 0.123	

Figure 3 The prevalence and correlations of dyad chronic diseases comorbidities. The O/E ratio was calculated to estimate conditional probabilities of combinations of two conditions and is equal to the ratio of observed and expected prevalence of co-modality.

conducting a bidirectional two-sample MR study, we attempted to exclude the effect of confounding factors to investigate the causal associations between hypertension and diabetes.

Initially, 62 SNPs were selected from the hypertension GWAS database (GWAS ID: finn-b-I9\_HYPTENS). Then, the known underlying confounding factors, such as age, body mass index (BMI),<sup>31</sup> obesity, overweight, Vitamin D, and sleep, were included in MR analysis to eliminate confounding SNPs, and 12 were identified and removed. Following overlap with the diabetes GWAS data (GWAS ID: finn-b-E4\_DIABETES), 10 SNPs were removed as palindromic. MR-PRESSO test results revealed no individual SNPs with significant pleiotropy. Finally, 40 SNPs were selected as IVs for MR analysis (The effect estimates of single SNPs are shown in Figure S2A). The overall *F*-statistic value of 12.20 is significantly higher than the critical value of 10, indicating no weak instrumental bias exists in IVs.

In the present study, three MR analysis methods were used to estimate the effect of hypertension on the development of diabetes mellitus: MR Egger, Weighted median, and IVW methods. The random effects model of the IVW method was used to investigate the effect of hypertension on diabetes, given heterogeneity (Cochran's Q = 80.875, p < 0.01). As shown in Figure 4A, the findings revealed hypertension as a significant predictor of diabetes (IVW, *OR [95% CI]*: 1.114 [1.049, 1.184], p < 0.001). The MR Egger method estimated an intercept of -0.0019 with a *p*-value of 0.8116, indicating a lack of statistical significance and implying that the IVs had no horizontal pleiotropic effects. Leave-one-out analysis (Figure S3A) and funnel plot (Figure S4A) demonstrated that the results were sufficiently robust.

We further analyzed the causal associations between diabetes mellitus and hypertension. The diabetes GWAS database yielded 58 SNPs. After comparing the results to the hypertension GWAS database, 15 confounding SNPs and seven palindromic SNPs were identified and removed. Two SNPs with significant pleiotropy (as determined by the MR-PRESSO Outlier Test, p < 0.05) were excluded. Finally, 34 SNPs were selected as IVs (Figure S2B) without




Figure 4 Scatter plots of estimated effect sizes among variables. Scatter plot revealing MR effect estimates of exposure over the outcome. Each variant-exposure association was plotted against the variant-outcome association, and the corresponding MR estimate for inverse variance weighted, MR Egger, weighted median, simple mode, and weighted mode. The slope indicates the size of the estimated effect of the exposure on outcome. The effect of (**A**) hypertension on diabetes, (**B**) diabetes on hypertension, (**C**) hypertension on triglycerides, (**D**) hypertension on stroke, (**E**) hypertension on ischemic stroke, and (**F**) hypertension on intracranial hemorrhages. The figure displays the correlation effect ( $\beta$ , beta) of the two conditions, with the slopes of the lines serving as indicators. The odds ratios (*ORs*) were calculated using the odds Ratio() function in R (version 4.2.3), where *OR* is equivalent to exp( $\beta$ ).

evidence of weak instrumental bias (F = 23.65). Conversely, diabetes mellitus was equally a risk factor for hypertension in MR analysis (IVW (random effects), *OR [95% CI]*: 1.118 [1.069, 1.187], p < 0.001, Figure 4B). There was no significant horizontal pleiotropy from IVs to outcome (intercept = -0.0070, p = 0.090), and the results appeared sufficiently robust (Figures S3B, and S4B).

#### Hypertension and Hyperlipidemia

Hyperlipidemia is a common chronic disease in the elderly. A report stated that people with hyperlipidemia have roughly twice the risk of developing cardiovascular disease (CVD) compared to those with normal total cholesterol levels in the United States.<sup>32</sup> Hyperlipidemia is characterized by an imbalance in blood cholesterol levels, including low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels. Hypertriglyceridemia and mixed hyperlipidemia are other types of hyperlipidemia that involve elevated cholesterol and triglyceride levels.<sup>32</sup> Elevated LDL-C levels can cause plaque buildup in arteries and are associated with an increased risk of atherosclerotic cardiovascular disease.<sup>32</sup> To date, no publication has investigated the causal association between hyperlipidemia are not currently being performed because of the possible lack of hyperlipidemia GWAS data. However, many observational studies have identified triglycerides (TG), cholesterol, and TG/HDL-C ratio as independent risk factors for hypertension, and the causal relationship between lipid-related factors (such as LDL-C, HDL-C, and triacylglycerols) and hypertension. Nonetheless, hyperlipidemia is a multivariate lipid effect, and previous univariate MR studies appear insufficiently convincing. Therefore, we included common hyperlipidemia-related lipid factors, namely, total cholesterol (TC), TG, LDL-C, and HDL-C, in a multivariate MR analysis.

A total of 1616 SNPs were selected from the GWAS database to represent four exposure variables: TC (GWAS ID: met-d-Total\_C), TG (GWAS ID: ieu-b-111), LDL-C (GWAS ID: ieu-b-110), and HDL-C (GWAS ID: ieu-b-109). The remaining 396 SNPs were included in the analysis after being removed for duplication, palindromic with intermediate allele frequencies, and association with potential confounding factors such as age, BMI, obesity, overweight, sleep, and dietary fiber.<sup>33</sup> Subsequently, 49 SNPs were removed for being palindromic from GWAS data of hyperlipidemia-related factors and hypertension (GWAS ID: finn-b-I9 HYPTENS). Finally, 347 SNPs were selected as IVs for MR analysis.

Multivariate MR revealed that high TG was a risk factor for hypertension (IVW, *OR [95% CI]*:1.262 [1.129, 1.411], p < 0.001) with no weak instrumental bias in IVs (F = 16.70), while the other three factors were not found to be causally associated with hypertension (IVW, *ORs [95% CI]*:0.830 [0.578, 1.191], p = 0.312 for TC; 1.115 [0.822, 1.513], p = 0.485 for LDL–C; and 0.953 [0.799, 1.136], p = 0.591 for HDL–C).

Subsequently, we used a two-sample MR method to investigate the plausible direct effects of hypertension on TG levels. We integrated confounding factors, such as cholesterol, to identify confounding SNPs and mitigate the influence of confounding variables. We eliminated four palindromic SNPs after intersection with TG GWAS. We included 22 SNPs (Figure S2C) as IVs in MR analysis after eliminating four SNPs due to significant horizontal pleiotropy. It should be noted that these IVs may exhibit a weak instrumental variable bias (F = 3.19). The findings indicated the absence of horizontal pleiotropy (intercept = -0.0039, p = 0.2328) but the presence of heterogeneity (Cochran's Q = 48.268, p < 0.001) in the IVs. Therefore, IVW random model was used to assess the effects of hypertension on TG levels. The results indicated that hypertension was not a significant predictor of TG level (OR [95% CI]:0.979 [0.956, 1.002], p = 0.074, Figure 4C), and the results appeared sufficiently robust (Figure S3C and S4C).

#### Hypertension and Stroke

Several studies have demonstrated that hypertension is the most important risk factor for all types of strokes.<sup>34–37</sup> High BP is the most significant risk factor for stroke and applies to both ischemic stroke and intracerebral hemorrhage. Significant risks include smoking, diabetes, hyperlipidemia, and physical inactivity.<sup>38</sup>

Twenty-seven SNPs associated with confounding factors, such as age, BMI, obesity, overweight, diabetes, cholesterol, TG, and sleep were excluded. Six palindromic SNPs were eliminated after harmonizing the SNPs between the exposure and outcome. The remaining 29 SNPs (Figure S2D) were analyzed as IVs, and there was no weak instrumental variable bias (F = 53.62). The IVs showed no significant horizontal pleiotropy (intercept = -0.0047, p = 0.6627) or heterogeneity (Cochran's Q = 31.374, p = 0.301). Therefore, the effect of hypertension on stroke was estimated using the fixed effects IVW method. As shown in Figure 4D, the results revealed that besides the IVW estimates (OR [95% CI]: 1.334 [1.235, 1.441], p < 0.001), all other methods, such as MR Egger (OR [95% CI]: 1.411 [1.083, 1.839], p < 0.05), weighted median (OR [95% CI]: 1.320 [1.182, 1.475], p < 0.001), simple mode (OR [95% CI]: 1.329 [1.067, 1.656], p < 0.05), and weighted mode (OR [95% CI]: 1.321 [1.073, 1.626], p < 0.05) indicated that hypertension was a notable risk factor for stroke.

Furthermore, we estimated the risk of hypertension for two types of strokes: ischemic stroke and intracerebral hemorrhage.<sup>38</sup> Two GWAS databases (ischemic stroke, GWAS ID: finn-b-I9\_STR\_EXH, and intracranial hemorrhage, GWAS ID: finn-b-I9\_OTHINTRACRA) derived from the corresponding two stroke types were collected for SNP selection of SNPs.

First, we investigated the effects of hypertension on ischemic stroke. 29 SNPs were included as IVs in the MR analysis (Figure S2E), with no weak instrumental variable bias (F = 20.78 > 10). No horizontal pleiotropic IVs were observed (intercept = 0.0002, p = 0.9906). Because IVs were heterogeneous (Cochran's Q = 41.493, p < 0.05), the random-effects IVW method was used to evaluate the effect of hypertension on ischemic stroke. The findings revealed that hypertension had a significant effect on ischemic stroke (OR [95% CI], 1.299 [1.161–1.454], p < 0.001, Figure 4E). The effect of hypertension on intracranial hemorrhage was investigated. Similarly, 29 SNPs were selected as IVs in MR analysis (Figure S2F) with potentially weak instrumental variable bias (F = 0.41 < 10). Horizontal pleiotropy (intercept = 0.0361, p = 0.6070) and heterogeneity (Cochran's Q = 34.73, p = 0.178) of IVs were insignificant. The results of MR analysis suggested that hypertension was not a predictor of intracranial hemorrhage (Fixed-effect IVW, OR [95% CI]:1.172 [0.723, 1.899], p = 0.520, Figure 4F). Based on the leave-one-out analysis (Figure S3D–S3F) and funnel plot (Figure S4D–S4F), all the above results were found to be robust.

The graphical representation depicted in Figure 5A provides a comprehensive overview of the influence of hypertension on common comorbidities. Similarly, Figure 5B illustrates the effect of other illnesses on hypertension. As summarized in Figure 5C, hypertension mediated the causal association between multiple chronic diseases. Hypertension and diabetes have a bidirectional cause-and-effect relationship. Hypertension is a risk factor for stroke, particularly ischemic stroke. The hyperlipidemia-related factor TG influences hypertension.

### Discussion

Comorbidity, defined as multiple chronic diseases in an individual, has emerged as a prevalent global phenomenon, particularly among the elderly.<sup>3,4</sup> A cross-sectional community survey conducted in the present study revealed that the prevalence of comorbidity among the 12 chronic diseases investigated was 20.7% among individuals aged  $\geq 60$  years, indicating a heightened risk of chronic disease comorbidity among the local older adults. Therefore, relevant authorities must implement appropriate health management measures to combat the escalating threat of chronic disease.

Various factors such as smoking, alcohol consumption, diet, and exercise contribute to chronic diseases. However, the causal relationships between chronic illnesses have not been extensively studied because of the difficulty in designing rigorous longitudinal RCT to investigate their causal evidence. Consequently, the present study investigated the prevalence of chronic illness comorbidities and their causal associations using MR methods with a public GWAS database.

We examined MR evidence supporting a bidirectional relationship between T2D and hypertension. A prospective study demonstrated that higher blood pressure (BP) is a risk factor for T2D in middle-aged and elderly individuals.<sup>24</sup> Similar MR studies on the causal association between hypertension and T2D have also been reported, revealing that T2D may causally affect hypertension (*OR [95% CI]*, 1.07 [1.04–1.10]), whereas the relationship between hypertension and T2D is unlikely (0.96 [0.88–1.04]). There was also a counterargument that BP had BMI-independent causal effects on the risk of T2D.<sup>30</sup> The present study evaluated the causal relationship between hypertension and diabetes, contradicting previous findings. Variations in the sample sources, IVs, and effect estimation methods can cause discrepancies in the results of multiple MR studies.




Figure 5 Causal interaction effects among common comorbidities. (A). Estimates of the effect of hypertension on diabetes, hyperlipidemia-related factors (triglycerides), and stroke. (B). Estimates of the effects of diabetes mellitus and hyperlipidemia-related factors on hypertension. (C). The schematic diagram of the causal interaction effects of comorbidities of common chronic diseases.

A minor bidirectional causal relationship between hypertension and diabetes has also been validated. The current results are more reliable because we used more rigorous screening of SNPs, specifically by removing potential confounding SNPs, and we selected newer, larger samples for analysis. Numerous pathophysiological mechanisms have supported this association. Among these mechanisms, insulin resistance in the nitric-oxide pathway, the stimulatory effect of hyperinsulinemia on the sympathetic drive, smooth muscle growth, and sodium-fluid retention, pivotal involvement of purinergic signaling, and the excitatory effect of hyperglycemia on the renin-angiotensin-aldosterone system appear to mediate the causality between them. Moreover, obesity, inflammation, oxidative stress, and insulin resistance have been proposed as common pathways that mediate causality.<sup>39</sup> A comprehensive review provided evidence supporting the notion that insulin resistance is a critical link between hypertension and diabetes. Notably, insulin resistance is thought to play a critical role in developing and progressing hypertension-induced target organ damage such as left ventricular hypertrophy, atherosclerosis, and chronic kidney disease.

The present study had some limitations. One of the fundamental tenets of MR is that IVs should not be linked to potentially confounding variables. Considering the modest effect size (with an OR value of approximately one) observed

in the present and previous studies, the causal relationship between hypertension and diabetes requires further investigation owing to the possibility of unidentified confounding factors that could introduce bias. For instance, neuroinflammation may be a potential confounder because it uses the autonomic nervous system to mediate the development of diabetes and hypertension. Despite the efforts to account for all confounding factors, it remains challenging to conduct studies that completely exclude the impact of confounding SNPs in IVs. Nevertheless, the current study used the most common confounding factors, and the conclusions were considered reliable.

Hypertension and hyperlipidemia are common comorbidities among patients in China. TG and cholesterol levels are frequently used as biomarkers for hyperlipidemia detection. Despite the lack of publicly available genetic data on hyperlipidemia in MR studies, these biomarkers were used as variables. Consistent with previous observational studies, high TG levels were associated with an increased risk of hypertension. Genetic and observational data have highlighted the mediating role of pulse rate and lymphocyte count in the causal pathway from TG to BP.<sup>40</sup>

Nevertheless, the current findings contradict those of previous research and do not support cholesterol as a predictor of hypertension. After controlling for other variables, such as TG, the present study discovered that cholesterol levels were not predictors of hypertension. This inconsistency can be attributed to two factors. First, the results of observational studies provide causal indications rather than conclusive causal evidence. Second, univariate analysis does not account for potential underlying variables to the same extent as multivariate analysis.

The present MR analysis validated hypertension as a risk factor for stroke, consistent with previous research findings.<sup>34–37</sup> Previous MR studies investigated the causal association between BP and stroke (systolic BP, per 10 mmHg: *OR [95% CI]*, 1.35 [1.24–1.48]; diastolic BP, per 5 mmHg: *OR [95% CI]*, 1.20 [1.12–1.28]).<sup>41</sup> However, the current study focused on the causal relationship between hypertension and stroke rather than BP, which is more clinically relevant. Furthermore, the current findings indicate that hypertension is a predictive factor for ischemic stroke rather than for hemorrhagic stroke. This assertion is supported by an MR study that suggested that hypertensive disorders during pregnancy are also associated with an increased risk of ischemic stroke (*OR*, 1.27; 95% *CI*, 1.12–1.44).<sup>42</sup>

The present study proposed a causal paradigm for common chronic diseases in the elderly, as depicted in Figure 5C. The mediating role of hypertension in the causal association between multiple chronic diseases has been previously highlighted. Notably, there was a bidirectional cause-and-effect relationship between hypertension and diabetes. Furthermore, hypertension is a risk factor for ischemic stroke, with the hyperlipidemia-related factor, TG influencing hypertension. Given these findings, prioritizing hypertension prevention and control in the elderly is crucial for effective chronic disease management. Besides, unhealthy lifestyle habits often result in obesity, which is considered as the upstream pathophysiology of chronic diseases. Therefore, it is also crucial to manage upstream conditions such as abdominal obesity to control chronic diseases.

### **Abbreviations**

MR, Mendelian Randomization; NCDs, non-communicable chronic diseases; CVD, cardiovascular disease; RCTs, Randomized Controlled Trials; SNPs, single nucleotide polymorphisms; IVs, instrument variables; GWAS, genome-wide association study; IVW, inverse variance weighted; RR, risk ratios; O/E, observed-to-expected ratios; LD, linkage disequilibrium; BP, blood pressure; T2D, type 2 diabetes; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.

# **Data Sharing Statement**

The cross-sectional data during the current study are available from the author Junwang Gu (E-mail: gj\_one.gmu.edu.cn) upon reasonable request. Publicly available datasets were analyzed in MR study and can be obtained from <a href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</a>.

# **Ethics Approval and Consent to Participate**

The cross-sectional study protocol was approved by the Ethics Review Board of Gannan Medical University, and the study was performed following the tenets of the Declaration of Helsinki and relevant policies in China. Participants provided informed consent before data collection, and their personal information was maintained anonymously. The current Mendelian randomization study that analyzed publicly available summary-level data was exempt from ethical approval.

# Acknowledgments

We thank the IEU Open GWAS Project (https://gwas.mrcieu.ac.uk/) for providing summary statistics.

### Funding

This work was supported by the Science and Technology Project of Jiangxi Province Educational Department of China (NO. GJJ201547, GJJ180825) and the Open Project of Key Laboratory of Cardiovascular and Cerebrovascular Disease Prevention and Control in Gannan Medical University, Ministry of Education (NO. XN201801, XN202021).

# Disclosure

The authors report no conflicts of interest in this work.

# References

- 1. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. *Lancet.* 2014;384(9937):45–52. doi:10.1016/S0140-6736(14)60648-6
- Gaziano TA, Pagidipati N. Scaling up chronic disease prevention interventions in lower- and middle-income countries. Annu Rev Public Health. 2013;34(1):317–335. doi:10.1146/annurev-publhealth-031912-114402
- 3. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. *Ann Fam Med.* 2009;7(4):357–363. doi:10.1370/afm.983
- 4. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35(1):75-83. doi:10.1093/epirev/mxs009
- 5. Schafer I, von Leitner EC, Schon G, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. *PLoS One*. 2010;5(12):e15941. doi:10.1371/journal.pone.0015941
- 6. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012;2(2):1143-1211.
- 7. Westreich D. Epidemiology by Design: A Causal Approach to the Health Sciences. Oxford University Press; 2019.
- Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886. doi:10.1056/NEJM200006223422506
- 9. Budu-Aggrey A, Paternoster L. Research techniques made simple: using genetic variants for randomization. J Invest Dermatol. 2019;139(7):1416–1421 e1411. doi:10.1016/j.jid.2019.03.1138
- 10. van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany. *BMC Public Health*. 2011;11(1):101. doi:10.1186/1471-2458-11-101
- 11. Feng R, Lu M, Xu J, et al. Pulmonary embolism and 529 human blood metabolites: genetic correlation and two-sample Mendelian randomization study. *BMC Genom Data*. 2022;23(1):69. doi:10.1186/s12863-022-01082-6
- 12. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol*. 2011;40 (3):755–764. doi:10.1093/ije/dyr036
- 13. Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics*. 2016;32 (20):3207–3209. doi:10.1093/bioinformatics/btw373
- 14. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics*. 2019;35(22):4851–4853. doi:10.1093/bioinformatics/btz469
- 15. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet*. 2018;50(5):693–698. doi:10.1038/s41588-018-0099-7
- 16. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet*. 2014;23 (R1):R89–98. doi:10.1093/hmg/ddu328
- 17. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–525. doi:10.1093/ije/dyv080
- 18. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. 2018;7. doi:10.7554/eLife.34408
- 19. Hemani G, Tilling K, Davey Smith G, Li J. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS Genet.* 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
- 20. Yildiz M, Esenboga K, Oktay AA. Hypertension and diabetes mellitus: highlights of a complex relationship. *Curr Opin Cardiol.* 2020;35 (4):397–404. doi:10.1097/HCO.00000000000748
- 21. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601-610. doi:10.1016/S0140-6736(12)60987-8
- 22. Wise J. High blood pressure is linked to increased risk of diabetes. BMJ. 2015;351:h5167. doi:10.1136/bmj.h5167
- 23. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications. *Hypertens Res.* 2018;41(3):147–156. doi:10.1038/s41440-017-0008-y
- 24. Yang X, Chen J, Pan A, et al. Association between higher blood pressure and risk of diabetes mellitus in middle-aged and elderly Chinese adults. *Diabetes Metab J.* 2020;44(3):436–445. doi:10.4093/dmj.2019.0081
- 25. Chen Y, Ma J, Lu D, Fang Y. The risk factors of type 2 diabetes in hypertensive subjects. Front Endocrinol. 2022;13:901614. doi:10.3389/ fendo.2022.901614
- 26. Tian X, Zuo Y, Chen S, et al. Hypertension, arterial stiffness, and diabetes: a prospective cohort study. *Hypertension*. 2022;79(7):1487–1496. doi:10.1161/HYPERTENSIONAHA.122.19256
- 27. Toyama M, Watanabe S, Miyauchi T, et al. Diabetes and obesity are significant risk factors for morning hypertension: from Ibaraki Hypertension Assessment Trial (I-HAT). *Life Sci.* 2014;104(1–2):32–37. doi:10.1016/j.lfs.2014.03.029

- 28. Li AL, Peng Q, Shao YQ, Fang X, Zhang YY. The interaction on hypertension between family history and diabetes and other risk factors. *Sci Rep.* 2021;11(1):4716. doi:10.1038/s41598-021-83589-z
- 29. Sun D, Zhou T, Heianza Y, et al. Type 2 diabetes and hypertension. Circ Res. 2019;124(6):930-937. doi:10.1161/CIRCRESAHA.118.314487
- 30. Jia Y, Guo D, Sun L, et al. Diet, lifestyle behaviours and other risk factors associated with type 2 diabetes beyond body mass index: a Mendelian randomization study. *Can J Diabetes*. 2022;46(8):822–828. doi:10.1016/j.jcjd.2022.06.001
- Huang J, Huffman JE, Huang Y, et al. Genomics and phenomics of body mass index reveals a complex disease network. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-35553-2
- 32. Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139-s148.
- 33. Chen G, Wang H, Zhang X, Yang ST. Nutraceuticals and functional foods in the management of hyperlipidemia. *Crit Rev Food Sci Nutr.* 2014;54 (9):1180–1201. doi:10.1080/10408398.2011.629354
- 34. Dubow J, Fink ME. Impact of hypertension on stroke. Curr Atheroscler Rep. 2011;13(4):298-305. doi:10.1007/s11883-011-0187-y
- Rantakomi SH, Laukkanen JA, Sivenius J, Kauhanen J, Kurl S. Alcohol consumption and the risk of stroke among hypertensive and overweight men. J Neurol. 2013;260(2):534–539. doi:10.1007/s00415-012-6672-6
- 36. Alloubani A, Saleh A, Abdelhafiz I. Hypertension and diabetes mellitus as a predictive risk factors for stroke. *Diabetes Metab Syndr*. 2018;12 (4):577–584. doi:10.1016/j.dsx.2018.03.009
- 37. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. *Neurology*. 2014;82(13):1153-1161. doi:10.1212/ WNL.00000000000268
- 38. Campbell BCV, Khatri P. Stroke. Lancet. 2020;396(10244):129-142. doi:10.1016/S0140-6736(20)31179-X
- 39. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? *Curr Atheroscler Rep.* 2012;14(2):160–166. doi:10.1007/s11883-012-0227-2
- 40. Liu LY, Gu Q, Hu X, Fan J, Liu XZ. Potential mediators of causal associations of circulating triglycerides with blood pressure: evidence from genetic and observational data. *Hypertension*. 2022;79(11):2439–2447. doi:10.1161/HYPERTENSIONAHA.122.19510
- 41. Wan EYF, Fung WT, Schooling CM, et al. Blood pressure and risk of cardiovascular disease in UK biobank: a mendelian randomization study. *Hypertension*. 2021;77(2):367–375. doi:10.1161/HYPERTENSIONAHA.120.16138
- 42. Rayes B, Ardissino M, Slob EAW, Patel KHK, Girling J, Ng FS. Association of hypertensive disorders of pregnancy with future cardiovascular disease. *JAMA Network Open.* 2023;6(2):e230034. doi:10.1001/jamanetworkopen.2023.0034

Diabetes, Metabolic Syndrome and Obesity



Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal